Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A safety and bioequivalence study of doxorubicin hydrochloride liposome injection (TLC177) in patients with advanced ovarian carcinoma

Next Previous
X
Search
Trial Profile

A safety and bioequivalence study of doxorubicin hydrochloride liposome injection (TLC177) in patients with advanced ovarian carcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 19 May 2017 According to a Taiwan Liposome Company media release, based on the data from this study, the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for TLC177 (liposomal doxorubicin) in the treatment of breast cancer and ovarian cancer.
    • 06 Oct 2016 New trial record
    • 02 Sep 2016 Preliminary results published in a Taiwan Liposome Company media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top